A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C.W., le Roux, Carel W., Violante Ortiz, Rafael, Jensen, Christine Bjørn, Wilding, John P.H.·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1411892

Cited by (1,037)

Items 301–400 of 1,037

  1. Weight, Shape, and Body Composition Changes at Menopause
    Anna J. Fenton · 2021 · Journal of Mid-life Health
  2. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
    Ndumele, Chiadi E., Rodriguez, Fatima, Dixon, Dave L., Khan, Sadiya S., Mukherjee, Debabrata, Bajaj, Mandeep, Bangalore, Sripal, Bozkurt, Biykem, Breathett, Khadijah, Clarke, Shoa L. et al. · 2026 · JACC
  3. Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis
    Khera, Rohan, Pandey, Ambarish, Chandar, Apoorva K., Murad, Mohammad H., Prokop, Larry J., Neeland, Ian J., Berry, Jarett D., Camilleri, Michael, Singh, Siddharth · 2018 · Gastroenterology
  4. Weight maintenance: challenges, tools and strategies for primary care physicians
    Taraneh Soleymani, Sunil Daniel, William Timothy Garvey · 2015 · Obesity Reviews
  5. Enteroendocrine cell regulation of the gut-brain axis
    Joshua R. Barton, Anne Londregan, Tyler D. Alexander, Ariana A. Entezari, Manuel Covarrubias, Scott Arthur Waldman · 2023 · Frontiers in Neuroscience
  6. An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
    Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, Maxime Taquet, Amanda Adler, Ivan G. Koychev, Rachel Upthegrove, Marco Solmi, Robert Ali McCutcheon, Toby Pillinger et al. · 2025 · Nature Mental Health
  7. Obesity: pathophysiology and therapeutic interventions
    Kong, Yue, Yang, Haokun, Nie, Rong, Zhang, Xuxiang, Zuo, Fan, Zhang, Hongtao, Nian, Xin · 2025 · Molecular Biomedicine
  8. Prevención, diagnóstico y tratamiento de la obesidad. Posicionamiento de la Sociedad Española para el Estudio de la Obesidad de 2016
    Albert Lecube, Susana Monereo, Miguel Ángel Rubio, Purificación Martínez de Icaya, Amelia Martí, Javier Salvador, Lluís Masmiquel, Albert Goday, Diego Bellido, Empar Lurbe et al. · 2016 · Endocrinología Diabetes y Nutrición
  9. Perspectives in GLP-1 Research: New Targets, New Receptors
    Giulia Cantini, Edoardo Mannucci, Michaela Luconi · 2016 · Trends in Endocrinology and Metabolism
  10. Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
    Garito, Tania, Roubenoff, Ronenn, Hompesch, Marcus, Morrow, Linda, Gomez, Katherine, Rooks, Daniel, Meyers, Charles, Buchsbaum, Monte S., Neelakantham, Srikanth, Swan, Therese et al. · 2018 · Diabetes, Obesity and Metabolism
  11. The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers
    Tan, Tricia, Behary, Preeshila, Tharakan, George, Minnion, James, Al-Najim, Werd, Albrechtsen, Nicolai J. Wewer, Holst, Jens J., Bloom, Stephen R. · 2017 · The Journal of Clinical Endocrinology & Metabolism
  12. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
    Perreault, Leigh, Davies, Melanie, Frias, Juan P., Laursen, Peter Nørkjaer, Lingvay, Ildiko, Machineni, Sriram, Varbo, Anette, Wilding, John P.H., Wallenstein, Signe Olrik Rytter, le Roux, Carel W. · 2022 · Diabetes Care
  13. Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial
    Steinberg, William M., Buse, John B., Ghorbani, Marie Louise Muus, Ørsted, David D., Nauck, Michael A., the LEADER Steering Committee, on behalf of the LEADER Trial Investigators · 2017 · Diabetes Care
  14. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
    Marco Castellana, Angelo Cignarelli, Francesco Brescia, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino · 2019 · Scientific Reports
  15. Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
    João Victor da Silva Guerra, Marieli M. G. Dias, Anna Julyana Viana Chianca Brilhante, Maiara Ferreira Terra, Marta García‐Arévalo, Ana Carolina Migliorini Figueira · 2021 · Nutrients
  16. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
    Chiadi E. Ndumele, Fátima Rodríguez, Dave L. Dixon, Sadiya S. Khan, Debabrata Mukherjee, Mandeep Singh Bajaj, Sripal Bangalore, Biykem Bozkurt, Khadijah K Breathett, Shoa L. Clarke et al. · 2026 · Circulation
  17. Why the NHS should do more bariatric surgery; how much should we do?:
    Richard Welbourn, Carel Wynand le Roux, Amanda Owen‐Smith, Sarah Wordsworth, Jane M. Blazeby · 2016 · BMJ
  18. A phase 3 randomized clinical trial using a o nce‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesity
    Roth, Christian L., Perez, Francisco A., Whitlock, Kathryn B., Elfers, Clinton, Yanovski, Jack A., Shoemaker, Ashley H., Abuzzahab, M. Jennifer · 2021 · Diabetes, Obesity and Metabolism
  19. Oxyntomodulin: actions and role in diabetes
    Holst, Jens J., Albrechtsen, Nicolai J.Wewer, Gabe, Maria Buur Nordskov, Rosenkilde, Mette Marie · 2018 · Peptides
  20. Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea
    Wenlong Jiang, Weiguo Li, Jing Cheng, Wen Li, Fangzhou Cheng · 2022 · Sleep And Breathing
  21. Current Treatments for Patients with Genetic Obesity
    Nathan Faccioli, Christine Poitou, Karine Clément, Béatrice Dubern · 2023 · Journal of Clinical Research in Pediatric Endocrinology
  22. Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non‐surgical and bariatric surgery patients
    Suliman, Mohamed, Buckley, Adam, Al Tikriti, Alia, Tan, Tricia, le Roux, Carel W., Lessan, Nader, Barakat, Maha · 2019 · Diabetes, Obesity and Metabolism
  23. Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study
    Sharma, Arya M., Bélanger, André, Carson, Veronica, Krah, Jodi, Langlois, Marie‐France, Lawlor, Diana, Lepage, Suzanne, Liu, Aiden, Macklin, David A., MacKay, Noel et al. · 2019 · Clinical Obesity
  24. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database
    Wei Chen, Peishan Cai, Wenbin Zou, Zhiwen Fu · 2024 · Frontiers in Endocrinology
  25. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
    Sven Francque, Luisa Vonghia · 2019 · Advances in Therapy
  26. The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity
    Chrysi C. Koliaki, Stavros Liatis, Μaria Dalamaga, Alexander D. Kokkinos · 2020 · Current Obesity Reports
  27. Brown rice compared to white rice slows gastric emptying in humans
    Elizabeth A. Pletsch, Bruce R. Hamaker · 2017 · European Journal of Clinical Nutrition
  28. Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes
    Cheang, Jia Ying, Moyle, Peter M. · 2018 · ChemMedChem
  29. Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real‐world setting: The XENSOR Study
    Gorgojo‐Martínez, Juan J., Basagoiti‐Carreño, Belen, Sanz‐Velasco, Alberto, Serrano‐Moreno, Clara, Almodóvar‐Ruiz, Francisca · 2019 · International Journal of Clinical Practice
  30. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
    Garg, Vinay, Verma, Subodh, Connelly, Kim · 2019 · Progress in Cardiovascular Diseases
  31. Leveraging the Gut to Treat Metabolic Disease
    Ruth E. Gimeno, Daniel A. Briere, Randy J. Seeley · 2020 · Cell Metabolism
  32. Plasma FGF21 levels in obese patients undergoing energy-restricted diets or bariatric surgery: a marker of metabolic stress?
    Ana Belen Crujeiras, Diego Gómez-Arbeláez, M. Ángeles Zulet, Marcos C. Carreira, Ignacio Sajoux, Daniel Antonio de Luis, Ana I. Castro, Javier Baltar, Iván Baamonde de la Torre, Aurelio M. Sueiro et al. · 2017 · International Journal of Obesity
  33. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
    Gao, Xueqin, Hua, Xiaoli, Wang, Xu, Xu, Wanbin, Zhang, Yu, Shi, Chen, Gu, Ming · 2022 · Frontiers in Pharmacology
  34. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States
    Kim, Nina, Wang, Jessie, Burudpakdee, Chakkarin, Song, Yan, Ramasamy, Abhilasha, Xie, Yanwen, Sun, Rochelle, Kumar, Neela, Wu, Eric Q, Sullivan, Sean D · 2022 · Journal of Managed Care & Specialty Pharmacy
  35. Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
    Hope, David C. D., Vincent, Matthew L., Tan, Tricia M. M. · 2021 · Frontiers in Endocrinology
  36. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study
    Baxter, Sarah M., Lund, Lars Christian, Andersen, Jacob H., Brix, Thomas H., Hegedüs, Laszlo, Hsieh, Miyuki Hsing-Chun, Su, Chris Tzu-Ting, Cheng, Michael Chun-Yuan, Chang, Zoe Chi-Jui, Lai, Edward Chia-Cheng et al. · 2025 · Thyroid®
  37. Contemporary pharmacological treatment and management of heart failure
    Biykem Bozkurt · 2024 · Nature Reviews Cardiology
  38. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
    Ananthi Anandhakrishnan, Márta Korbonits · 2016 · World Journal of Diabetes
  39. Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis
    Pipek, Leonardo Zumerkorn, Moraes, Walter Augusto Fabio, Nobetani, Rodrigo Massato, Cortez, Vitor Santos, Condi, Alberto Santos, Taba, João Victor, Nascimento, Rafaela Farias Vidigal, Suzuki, Milena Oliveira, do Nascimento, Fernanda Sayuri, de Mattos, Vitoria Carneiro et al. · 2024 · Scientific Reports
  40. What Is Food Noise? A Conceptual Model of Food Cue Reactivity
    Hayashi, Daisuke, Edwards, Caitlyn, Emond, Jennifer A., Gilbert-Diamond, Diane, Butt, Melissa, Rigby, Andrea, Masterson, Travis D. · 2023 · Nutrients
  41. Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
    Costa, Alessia, Ai, Minrong, Nunn, Nicolas, Culotta, Isabella, Hunter, Jenna, Boudjadja, Mehdi Boutagouga, Valencia-Torres, Lourdes, Aviello, Gabriella, Hodson, David J., Snider, Brandy M. et al. · 2022 · Molecular Metabolism
  42. The significance of beige and brown fat in humans
    Florian Wolfgang Kiefer · 2017 · Endocrine Connections
  43. What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
    Rune E. Kuhre, Carolyn Fiona Deacon, Jens Juul Holst, Natalia Petersen · 2021 · Frontiers in Endocrinology
  44. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC)
    Massimo Volpe, Giovanna Gallo · 2023 · Frontiers in Cardiovascular Medicine
  45. A systematic review and narrative synthesis of interventions for uncomplicated obesity: weight loss, well-being and impact on eating disorders
    Tina Peckmezian, Phillipa Hay · 2017 · Journal of Eating Disorders
  46. The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy
    Abbass, Nadia J., Nahlawi, Raya, Shaia, Jacqueline K., Allan, Kevin C., Kaelber, David C, Talcott, Katherine E., Singh, Rishi P. · 2025 · American Journal of Ophthalmology
  47. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update
    Pedersen, Sue D., Manjoo, Priya, Dash, Satya, Jain, Akshay, Pearce, Nicole, Poddar, Megha · 2025 · Canadian Medical Association Journal
  48. Longitudinal Analysis of Obesity Drug Use and Public Awareness
    Berning, Philipp, Adhikari, Rishav, Schroer, Adrian E., Jelwan, Yara A., Razavi, Alexander C., Blaha, Michael J., Dzaye, Omar · 2025 · JAMA Network Open
  49. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
    Takayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka, Takahiro Suzuki, Daisuke Yoneoka, Yuri Nishikawa, Wilson Wai San Tam, Jakub Morze, Andrzej Rynkiewicz, Yiqiao Xin et al. · 2021 · Cochrane Database of Systematic Reviews
  50. Role of glucagon-like peptide 1 receptor agonists in management of obesity
    Diana M. Isaacs, Lalita Prasad‐Reddy, Sneha Baxi Srivastava · 2016 · American Journal of Health-System Pharmacy
  51. The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial
    Whicher, Clare A., Price, Hermione C., Phiri, Peter, Rathod, Shanaya, Barnard‐Kelly, Katharine, Ngianga, Kandala, Thorne, Kerensa, Asher, Carolyn, Peveler, Robert C., McCarthy, Joanne et al. · 2021 · Diabetes, Obesity and Metabolism
  52. Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
    Wharton, Sean, Liu, Aiden, Pakseresht, Arash, Nørtoft, Emil, Haase, Christiane L., Mancini, Johanna, Power, G. Sarah, Vanderlelie, Sarah, Christensen, Rebecca A. G. · 2019 · Obesity
  53. Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain
    Erzsébet Farkas, Anett Szilvásy‐Szabó, Yvette Ruska, Richárd Sinkó, Morten Grønbech Rasch, Thomas Egebjerg, Charles Pyke, Balázs Gereben, Lotte Bjerre Knudsen, Csaba Fekete · 2020 · Brain Structure and Function
  54. Liraglutide for Weight Management in Children and Adolescents With Prader–Willi Syndrome and Obesity
    Gwénaëlle Diene, Moris Angulo, Paula M. Hale, Cecilie Heerdegen Jepsen, Paul Leslie Hofman, Anita C. S. Hokken‐Koelega, Chethana Kalmady Ramesh, Serap Turan, M. Tauber · 2022 · The Journal of Clinical Endocrinology & Metabolism
  55. Obesity in Adults: A 2022 Adapted Clinical Practice Guideline for Ireland
    Cathy Breen, Jean O’Connell, Justin Geoghegan, Donal Brendan O'Shea, Susie Birney, Louise Tully, Karen Gaynor, Mark O’Kelly, Grace O’Malley, Clare B. O’Donovan et al. · 2022 · Obesity Facts
  56. Obesity: Recent Advances and Future Perspectives
    Miodrag Janić, Andrej Janež, Mohamed El‐Tanani, Manfredi Rizzo · 2025 · Biomedicines
  57. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program
    Steinberg, William M., Rosenstock, Julio, Wadden, Thomas A., Donsmark, Morten, Jensen, Christine B., DeVries, J. Hans · 2017 · Diabetes Care
  58. Single Fluid-Filled Intragastric Balloon Safe and Effective for Inducing Weight Loss in a Real-World Population
    Eric J. Vargas, Carl M. Pesta, Ahmad H. Bali, Eric Ibegbu, Fateh Bazerbachi, Rachel Moore, Vivek Kumbhari, Reem Z. Sharaiha, Trace W. Curry, Gina DosSantos et al. · 2018 · Clinical Gastroenterology and Hepatology
  59. Cardiovascular outcome trials in obesity: A review
    Wilding, John P.H., Jacob, Stephan · 2021 · Obesity Reviews
  60. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
    Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, Ele Ferrannini, Michael Albrecht Nauck, Soo Kyung Lim · 2022 · Trends in Endocrinology and Metabolism
  61. Cardiovascular–Kidney–Metabolic Syndrome: A New Paradigm in Clinical Medicine or Going Back to Basics?
    Victoria Mutruc, Cristina Bologa, Victorița Șorodoc, Alexandr Ceasovschih, Bianca Codrina Morărașu, Laurențiu Șorodoc, Oana Catar, Cătălina Lionte · 2025 · Journal of Clinical Medicine
  62. Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
    Zhong, Ping, Zeng, Hai, Huang, Miaochun, Fu, Wenbin, Chen, Zhixia · 2022 · Endocrine
  63. The intersection of nonalcoholic fatty liver disease and obesity
    Jennifer Woo Baidal, Joel E. Lavine · 2016 · Science Translational Medicine
  64. Should bariatric surgery be performed in adolescents?
    Andrew James Beamish, Thomas Reinehr · 2017 · European Journal of Endocrinology
  65. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis
    Tzang, Chih-Chen, Wu, Pei-Hsun, Luo, Chiao-An, Chen, Zi-Ting, Lee, Yi-Ting, Huang, Ewen Shengyao, Kang, Yuan-Fu, Lin, Wei-Chen, Tzang, Bor-Show, Hsu, Tsai-Ching · 2025 · EClinicalMedicine
  66. New therapies for obesity
    Papamargaritis, Dimitris, le Roux, Carel W, Holst, Jens J, Davies, Melanie J · 2024 · Cardiovascular Research
  67. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study
    Moll, Hannah, Frey, Eliane, Gerber, Philipp, Geidl, Bettina, Kaufmann, Marco, Braun, Julia, Beuschlein, Felix, Puhan, Milo A., Yebyo, Henock G. · 2024 · eClinicalMedicine
  68. Near‐normalization of glycaemic control with glucagon‐like peptide‐1 receptor agonist treatment combined with exercise in patients with type 2 diabetes
    Pernille Mensberg, Signe Nyby, Peter Godsk Jørgensen, Heidi Storgaard, Magnus Thorsten Jensen, Jacob Sivertsen, Jens Juul Holst, Bente Kiens, Erik Arne Richter, Filip Krag Knop et al. · 2016 · Diabetes Obesity and Metabolism
  69. Clinical Impact of Liraglutide as a Treatment of Obesity
    Heshma Alruwaili, Babak Dehestani, Carel Wynand le Roux · 2021 · Clinical Pharmacology Advances and Applications
  70. Chronic Kidney Disease and Obesity
    Radovan Hojs, Robert Ekart, Sebastjan Bevc, Nina Vodošek Hojs · 2023 · The Nephron journals/Nephron journals
  71. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
    Lundkvist, Per, Pereira, Maria J., Katsogiannos, Petros, Sjöström, C. David, Johnsson, Eva, Eriksson, Jan W. · 2017 · Diabetes, Obesity and Metabolism
  72. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss
    Dilhana Badurdeen, Anna Carolina Hoff, Abdellah Hedjoudje, Atif Adam, Mohamad I. Itani, Jad Farha, Shahem Abbarh, Anthony Nicholas Kalloo, Mouen A. Khashab, Vikesh K. Singh et al. · 2020 · Gastrointestinal Endoscopy
  73. Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
    David S. Mathiesen, Asger Lund, Tina Vilsbøll, Filip Krag Knop, Jonatan Ising Bagger · 2021 · Frontiers in Endocrinology
  74. The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice
    Xinxin Yu, Shiuhwei Chen, Jan‐Bernd Funcke, Leon Gabriel Straub, Valentina Pirro, Margo P. Emont, Brian A. Droz, Kyla A.L. Collins, Chanmin Joung, Mackenzie Jo Pearson et al. · 2024 · Cell Metabolism
  75. Management of obesity in adult Asian Indians
    S. Behl, Anoop Misra · 2017 · Indian Heart Journal
  76. Recent Updates on Obesity Treatments: Available Drugs and Future Directions
    Nathalia Romanelli Vicente Dragano, Johan Fernø, Carlos Diéguez, Miguel López, Edward Milbank · 2020 · Neuroscience
  77. Tirzepatide Once Weekly for the Treatment of Obesity
    2022 · New England Journal of Medicine
  78. One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
    Gasoyan, Hamlet, Pfoh, Elizabeth R., Schulte, Rebecca, Le, Phuc, Butsch, W. Scott, Rothberg, Michael B. · 2024 · JAMA Network Open
  79. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Dong, Yajie, Lv, Qingguo, Li, Sheyu, Wu, Yuan, Li, Ling, Li, Juan, Zhang, Fang, Sun, Xin, Tong, Nanwei · 2017 · Clinics and Research in Hepatology and Gastroenterology
  80. The Regulation of Peripheral Metabolism by Gut-Derived Hormones
    Sun, Emily W. L., Martin, Alyce M., Young, Richard L., Keating, Damien J. · 2019 · Frontiers in Endocrinology
  81. The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care
    Tania Markovic, Joseph Proietto, John B. Dixon, Georgia Rigas, Gary Deed, Jeffrey M. Hamdorf, Erica Bessell, Nathalie V. Kizirian, Sofianos Andrikopoulos, Stephen Colagiuri · 2022 · Obesity Research & Clinical Practice
  82. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials
    Paschalis Karakasis, Dimitrios Patoulias, Konstantinos Pamporis, Panagiotis Stachteas, Konstantinos I. Bougioukas, Aleksandra N. Klisic, Nikolaos Fragakis, Manfredi Rizzo · 2023 · Metabolism
  83. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome
    Elizabeth Mary Lamos, Rana Malek, Stephen N. Davis · 2017 · Expert Review of Clinical Pharmacology
  84. Type 2 Diabetes
    Sandeep S. Vijan · 2019 · Annals of Internal Medicine
  85. Physiology of the Incretin Hormones, GIP and GLP ‐1—Regulation of Release and Posttranslational Modifications
    Jens Juul Holst, Nicolai J. Wewer Albrechtsen, METTE MARIE ROSENKILDE, Carolyn Fiona Deacon · 2019 · Comprehensive physiology
  86. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
    Horn, Deborah B, Ryan, Donna H, Kis, Sanja Giljanovic, Alves, Breno, Mu, Yiming, Kim, Sin Gon, Aberle, Jens, Bain, Stephen C, Allen, Sheryl, Sarker, Elizabeth et al. · 2025 · The Lancet
  87. Long-term effects of weight-reducing drugs in people with hypertension
    Siebenhofer, Andrea, Winterholer, Sebastian, Jeitler, Klaus, Horvath, Karl, Berghold, Andrea, Krenn, Cornelia, Semlitsch, Thomas · 2021 · Cochrane Database of Systematic Reviews
  88. Understanding the pathophysiological mechanisms of cardiometabolic complications in obstructive sleep apnoea: towards personalised treatment approaches
    Silke Ryan, Eoin P. Cummins, Ramón Farré, Alex Gileles‐Hillel, Jonathan C. Jun, Henrik Oster, Jean‐Louis Pépin, David William Ray, Sirimon Reutrakul, Manuel Sánchez‐de‐la‐Torre et al. · 2020 · European Respiratory Journal
  89. Proglucagon-Derived Peptides as Therapeutics
    Ryan A. Lafferty, Finbarr P.M. O'Harte, Nigel Irwin, Victor A. Gault, Peter R. Flatt · 2021 · Frontiers in Endocrinology
  90. Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: An updated systematic review and meta-analysis
    Park, Jeayoung, Ntelis, Spyridon, Yunasan, Elvina, Downton, Katherine D, Yip, Terry Cheuk-Fung, Munir, Kashif M, Haq, Nowreen · 2023 · The Journal of Clinical Endocrinology & Metabolism
  91. Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment
    Levi, Jacob, Wang, Junzheng, Venter, Francois, Hill, Andrew · 2023 · Obesity
  92. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial.
    Nauck, Michael A., Muus Ghorbani, Marie Louise, Kreiner, Eskil, Saevereid, Hans A., Buse, John B., the LEADER Publication Committee on behalf of the LEADER Trial Investigators · 2019 · Diabetes Care
  93. Allelic variant in the glucagon‐like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study
    Victor G Chedid, Prakhar Vijayvargiya, Paula Carlson, Kathleen Van Malderen, Andres J Acosta, Alan R. Zinsmeister, Michael Camilleri · 2018 · Neurogastroenterology & Motility
  94. Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway
    Yaru Wu, Xiaoyun Shi, Chunyan Ma, Yue Zhang, Rui‐Xia Xu, Jian‐Jun Li · 2019 · Cardiovascular Diabetology
  95. 7. Obesity Management for the Treatment of Type 2 Diabetes
    American Diabetes Association · 2016 · Diabetes Care
  96. Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis
    Derin Karacabeyli, Diane V. Lacaille · 2023 · JCR Journal of Clinical Rheumatology
  97. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis
    Congqin Chen, Rijing Zhou, Fang Fu, Jie Xiao · 2023 · European Psychiatry
  98. Weight Loss, Satiety, and the Postprandial Gut Hormone Response After Esophagectomy
    Jessie Andrea Elliott, Neil Gerard Docherty, Hans‐Georg Eckhardt, Suzanne L. Doyle, Emer M. Guinan, Narayanasamy Ravi, John Vincent Reynolds, Carel Wynand le Roux · 2016 · Annals of Surgery
  99. Medical Management of Diabesity: Do We Have Realistic Targets?
    Joseph M Pappachan, Ananth Viswanath · 2017 · Current Diabetes Reports
  100. Obesity and Reproduction
    NEAL G. MAHUTTE, Carole Kamga-Ngandé, Arya Mitra Sharma, Camille V Sylvestre · 2018 · Journal of Obstetrics and Gynaecology Canada